340 related articles for article (PubMed ID: 32376973)
1. In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever.
Baral P; Pavadai E; Gerstman BS; Chapagain PP
Sci Rep; 2020 May; 10(1):7667. PubMed ID: 32376973
[TBL] [Abstract][Full Text] [Related]
2. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
3. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.
Ibukun FI
Viruses; 2020 Mar; 12(4):. PubMed ID: 32244402
[TBL] [Abstract][Full Text] [Related]
4. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
5. Identification of Common CD8
Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
[TBL] [Abstract][Full Text] [Related]
6. HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2
Wauquier N; Petitdemange C; Tarantino N; Maucourant C; Coomber M; Lungay V; Bangura J; Debré P; Vieillard V
EBioMedicine; 2019 Feb; 40():605-613. PubMed ID: 30711514
[TBL] [Abstract][Full Text] [Related]
7. Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
Botten J; Alexander J; Pasquetto V; Sidney J; Barrowman P; Ting J; Peters B; Southwood S; Stewart B; Rodriguez-Carreno MP; Mothe B; Whitton JL; Sette A; Buchmeier MJ
J Virol; 2006 Sep; 80(17):8351-61. PubMed ID: 16912286
[TBL] [Abstract][Full Text] [Related]
8. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
[TBL] [Abstract][Full Text] [Related]
9. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
[TBL] [Abstract][Full Text] [Related]
10. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
11. Current research for a vaccine against Lassa hemorrhagic fever virus.
Warner BM; Safronetz D; Stein DR
Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
[TBL] [Abstract][Full Text] [Related]
12. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
13. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
14. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
15. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
[TBL] [Abstract][Full Text] [Related]
16. Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach.
Adhikari UK; Rahman MM
Infect Genet Evol; 2017 Dec; 56():75-91. PubMed ID: 29107145
[TBL] [Abstract][Full Text] [Related]
17. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
18. Advanced vaccine candidates for Lassa fever.
Lukashevich IS
Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
[TBL] [Abstract][Full Text] [Related]
19. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
[TBL] [Abstract][Full Text] [Related]
20. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
